Sonodynamic Therapy for the Treatment of Intracranial Gliomas.
High-grade gliomas are the most common and aggressive malignant primary brain tumors. Current therapeutic schemes include a combination of surgical resection, radiotherapy and chemotherapy; even if major advances have been achieved in Progression Free Survival and Overall Survival for patients harboring high-grade gliomas, prognosis still remains poor; hence, new therapeutic options for malignant gliomas are currently researched. Sonodynamic Therapy (SDT) has proven to be a promising treatment combining the effects of low-intensity ultrasound waves with various sound-sensitive compounds, whose activation leads to increased immunogenicity of tumor cells, increased apoptotic rates and decreased angiogenetic potential. In addition, this therapeutic technique only exerts its cytotoxic effects on tumor cells, while both ultrasound waves and sensitizing compound are non-toxic per se. This review summarizes the present knowledge regarding mechanisms of action of SDT and currently available sonosensitizers and focuses on the preclinical and clinical studies that have investigated its efficacy on malignant gliomas. To date, preclinical studies implying various sonosensitizers and different treatment protocols all seem to confirm the anti-tumoral properties of SDT, while first clinical trials will soon start recruiting patients. Accordingly, it is crucial to conduct further investigations regarding the clinical applications of SDT as a therapeutic option in the management of intracranial gliomas.
["D'Ammando|Antonio|A|", 'Raspagliesi|Luca|L|', 'Gionso|Matteo|M|0000-0002-1749-7418', 'Franzini|Andrea|A|', 'Porto|Edoardo|E|', 'Di Meco|Francesco|F|0000-0001-6213-5793', 'Durando|Giovanni|G|0000-0001-6324-0827', 'Pellegatta|Serena|S|0000-0001-7804-9486', 'Prada|Francesco|F|']
sonodynamic therapy gliomas 5-aminolevulinic acid cavitation fluorescein